ABSTRACT -Aetiology is the main determinant of morbidity and mortality in convulsive status epilepticus (CSE) but longer seizure durations may also increase risk of worse outcome. Thirty minutes of seizure activity is usually the time period used in longstanding definitions of CSE but it is not acceptable to wait for 30 minutes before treatment. Whilst intravenous therapy is best, pre-hospital treatment by a non-intravenous route is most practical in treating children. Benzodiazepines are the main class of first-line emergency antiepileptic drugs. This review will examine the available data on benzodiazepines according to: stability in the conditions of the emergency room services, drug absorption via non-intravenous route, clinical efficacy and safety, and ease of delivery and social acceptability.
Convulsive status epileptics (CSE) is associated with increased morbidity and mortality (Raspall-Chaure et al., 2006) . Whilst underlying aetiology is the main determinant of morbidity and mortality, experimental and clinical data indicate that longer seizure durations also increase the risk of a worse outcome (Lothman, 1990) . Thirty minutes of seizure activity is the time from which permanent brain injury can be observed and hence the reason why this time period is used in longstanding definitions of status epilepticus, particularly for epidemiological studies. However, it is not acceptable to wait for 30 minutes before treatment. Since 80% of seizures that do not stop within five minutes of onset continue for at least 30 minutes (Shinnar, 2007) and the longer seizures continue the more difficult they are to stop, there has been the emergence of an operational definition of CSE for treatment purposes to be based around a 5-minute threshold (Lowenstein et al., 1999) . Since most seizures start outside of the hospital/clinical setting (Raspall-Chaure et al., 2007) , it is imperative that in order to minimise seizure duration, treatment should be started prior to arrival at the hospital (Treiman et al., 1998; Chin et al., 2004a; Chin et al., 2008) . Whilst there is clear evidence that intravenous therapy is best (Yoong et al., 2009) , pre-hospital treatment by a non-intravenous route is most desirable since intravenous access poses a major challenge in a child experiencing seizures, particularly in children under the age of 5 years, when CSE is most common (Chin et al., 2004b; Chin et al., 2006) . Benzodiazepines are the main class of first-line antiepileptic drugs (AEDs) used for the emergency treatment of seizures because they have a rapid onset of action, have good efficacy, and are easy to prepare and administer by non-intravenous routes. The first licensed non-intravenous benzodiazepine preparation was rectal diazepam, and for many years was considered the gold standard for pre-hospital treatment (Shorvon, 2013) . However, new benzodiazepines have emerged (midazolam, clonazepam, and lorazepam) with alternative delivery routes (intranasal, buccal/oromucosal, sublingual, and intramuscular) . This review will examine the available data according to: -stability in the conditions of the emergency room services (EMS); -rapid drug absorption via non-intravenous route ; -proven clinical efficacy and safety; -ease of delivery route and social acceptability.
Stability in the conditions of the EMS
Rectal diazepam gel is stable under the temperature and light exposure conditions found in ambulances. When exposed to a freeze-thaw cycle, hard freeze (-30 • C for 72 hours), extreme light exposure, and longterm evaluation at either 30
• C or 40
• C, diazepam gel concentration always exceeded 95% of label, with no substantial changes in excipients or physicochemical properties (Alldredge et al., 2002) . Similarly, when exposed to ambient ambulance conditions during the spring/summer months in 14 metropolitan areas across the United States, midazolam and lorazepam were generally stable. There was no degradation in a non-commercially available Table 1 . Bioavailability, time to maximum blood concentration (T max ), and plasma half life (T 1/2 ) of buccal midazolam, intranasal midazolam, sublingual lorazepam, sublingual clonazepam drops, and rectal diazepam.
Oromucosal midazolam hydrochloride

Intranasal midazolam
Clonazepam drops
Fast-dissolving drug formulation Lorazepam
Rectal diazepam (Viropharma, 2011 ) (Wermeling et al., 2006 ) (Tassinari, 1998; Greenblatt, 1982) (Wermeling et al., 2006; Riss et al., 2008; Viropharma, 2011 For both children and adults, there is some evidence of inter-and intra-subject variability with regards to the effective dose and speed of onset of sublingual lorazepam (Greenblatt et al., 1982; Camu et al., 1988; Yager and Seshia, 1988) . In a study of 10 children, 8 had a latency of 30-60 minutes in terminating serial seizures (Yager and Seshia, 1988) . In a randomised, single, fiveway crossover study comparing the pharmacokinetics of two forms of sublingual lorazepam compared to intravenous, intramuscular, and oral lorazepam, 10 healthy adult volunteers each received a modest dose of 2 mg of lorazepam administered by each route, with sequential phlebotomy to assess levels. Of those given standard oral tablets of lorazepam administered sublingually, there was a lag time of 22.7±5.1 minutes from administration to the start of absorption in nine of the 10 volunteers. When they were given a special tablet preparation delivered sublingually, 8 showed delayed absorption of 14.9±3.5 minutes. There was no lag time for the intravenous nor intramuscular delivery routes. All subjects reported mild to moderate discomfort when given the drug intramuscularly. All routes exhibited similar peak drug concentrations, with the pharmacokinetics of the sublingual routes being similar to that of the oral route, which in turn, had a slower time-to-peak concentration compared to intramuscular lorazepam, although this was not statistically significant (Greenblatt et al., 1982) . This study suggests that if a preparation of lorazepam that undergoes rapid dissolution is available, it may be a useful clinical alternative to intramuscular/intravenous lorazepam. Fast-dissolving drug formulation (FDDF) lorazepam may be one such preparation but its absorption can be variable. In a study comparing the pharmacokinetics of FDDF and intravenous lorazepam as anaesthetic premedication, 8 adult surgical patients were given 4 mg sublinguales FDDF lorazepam and 8 were given 4 mg intravenous lorazepam. The absorption of sublingual FDDF lorazepam was rapid in half of the patients and provided a high plasma concentration of lorazepam (Cmax: 61.8±16.2 ng/mL) in a short time interval (Tmax: 58±39 min). However, in the other half, the absorption was slow with a low plasma concentration (Cmax: 39.5±17.2 ng/mL) with a variable lag time (Tmax: 360±69 min). This variability in absorption might explain why premedication with FDDF lorazepam is sometimes less effective than expected (Camu et al., 1988) , and could theoretically result in similar problems in the acute treatment of seizures. In a study on the pharmacokinetics of buccal midazolam, 10 healthy adult volunteers were given 10 mg of buccal/sublingual midazolam hydrochloride. There was a rapid increase in venous blood concentrations for the first 20-30 minutes following treatment. However, preceding the venous spike, spectral analysis identified EEG changes at 8-to 30-Hz frequencies, 5-10 minutes into the test, but not in control subjects (Scott et al., 1998) . These data prove that there is a rapid cerebral effect of midazolam hydrochloride and this occurs before a detectable venous surge. This may be attributable to the highly lipophilic, closed-ring form that midazolam hydrochloride assumes when it becomes absorbed into the circulation (Scott et al., 1998) . To the author's knowledge, there is, to date, no peer-reviewed similar published data on buccal midazolam maleate.
Rapid drug absorption and action via non-intravenous route
Proven clinical efficacy and safety
The duration of action of rectal diazepam is less than 2 hours, for buccal midazolam hydrochloride is 3 to 4 hours, and is longer for clonazepam drops (24 hours), and even longer for sublingual FDDF lorazepam (up to 72 hours). Duration of action is not correlated with the plasma concentration-time profiles of these drugs (Rey et al., 1999) . In principle, the longer duration of action of midazolam, clonazepam, and lorazepam may favour the use of these as alternatives to diazepam, particularly if they are available in a suitable non-intravenous rapidly absorbable form. In support of this, a metanalysis of six studies comparing non-intravenous midazolam and rectal or intravenous diazepam showed that midazolam was superior to diazepam in achieving seizure cessation (risk ratio: 1.52; 95% CI: 1.27-1.82). However, there are few randomised controlled trials that compare the different benzodiazepines and different administration routes for efficacy and safety in the emergency treatment of seizures in children. Those available are summarised below.
Intranasal midazolam versus rectal diazepam
In a prospective randomised study comparing intranasal midazolam versus rectal diazepam for the home treatment of acute seizures in paediatric patients with epilepsy, 358 children who attended a paediatric neurology clinic were prescribed home emergency treatment for their next seizure (Holsti et al., 2010) . Carers were randomised to use either 0.2 mg/kg of intranasal midazolam up to a maximum of 10 mg or 0.3 to 0.5 mg/kg of rectal diazepam, up to a maximum of 20 mg RD (maximum, 20 mg) for their child's seizure at home if it lasted more than five minutes. Ninety-two carers gave emergency treatment and completed the study; 50 administered intranasal midazolam and 42 gave rectal diazepam. Four died during the study without having used emergency medication, 254 did not receive emergency medication during the study, and 8 withdrew from the study. There was no statistically significant difference in time to treatment administration, time from treatment to seizure cessation, or efficacy between intranasal midazolam and rectal diazepam. Using an 11-point nominal scale to investigate ease of administration and overall carer satisfaction, carer scores were higher with intranasal midazolam compared to rectal diazepam for both ease of administration (10 vs. 9; p=0.02) and satisfaction (9.3 vs. 7.3; p=0.02) . Four children (8%) treated with intranasal midazolam required oxygen or intubation for respiratory complications, compared to one (2%) treated with rectal diazepam (the difference was not statistically significant). (Lahat et al., 2000; Mahmoudian and Zadeh, 2004) . In both, the end point was seizure termination within 10 minutes of treatment. The study by Lahat and colleagues was restricted to febrile seizures whilst Mahmoudian and Zaden included febrile and afebrile seizures. Both studies found remarkably high seizure termination rates when either drug was used. In particular, the study by Mahmoudian and colleagues reported seizure termination within 10 minutes of treatment in 100% of patients treated with either intranasal midazolam or intravenous diazepam. This is much higher than that found in any other study examining the efficacy of either drug for the emergency treatment of seizures. Both studies found that buccal midazolam was quicker to administer than intravenous diazepam. However, Mahmoudian and Zadeh found that the interval between treatment and seizure termination was longer with those treated with buccal midazolam (3.6 minutes) compared to those given intravenous diazepam (2.9 minutes) (p=0.007).
Intranasal midazolam versus intravenous diazepam
Increased blood flow to the nasal mucosa during an upper respiratory tract infection may aid drug absorption but nasal secretions may theoretically dilute the midazolam solution, thereby reducing contact with the absorptive nasal mucosal surface (Lahat et al., 2000) .
In the study by Lahat and colleagues, most of the 26 children treated with intranasal midazolam had an upper respiratory tract infection, of which only 3 had poor seizure control which was attributable to presumed ineffective absorption, however, there were R.F. Chin no confirmatory drug levels. Nasal irritation was not investigated in either of the trials on intranasal midazolam described above (Lahat et al., 2000; Mahmoudian and Zadeh, 2004; Holsti et al., 2010) . However, there is a potential for irritation to the nares, including burning sensation and lacrimation attributable to the acidic pH (3.5) of midazolam solution (Lugo et al., 1993) . Table 3 summarises studies comparing buccal midazolam versus rectal diazepam for emergency seizure treatment (Scott et al., 1999; McIntyre et al., 2005; Mpimbaza et al., 2008; Ashrafi et al., 2010) . Except for the study by Ashrafi and colleagues in which buccal midazolam maleate was used, all the studies used buccal midazolam hydrochloride. In all the studies, the primary endpoint was clinical cessation of motor activity within 5-10 minutes of administration. Together, these data provide strong evidence that buccal midazolam is superior or, at the very least, as effective as rectal diazepam. Amongst these studies, one was carried out in a residential school for children with severe epilepsy, whilst the others were carried out in the accident and emergency setting where participants are likely to have difficult-to-control seizures because of the length of seizure activity prior to arrival at hospital. Thus, although there are no trials based on the general population, it would be reasonable to surmise from the available data that buccal midazolam would be better for out-of-hospital treatment. The results of the Ugandan study (Mpimbaza et al., 2008) , which arguably had the best design since it was blinded and had the largest sample size, show that buccal midazolam was superior to diazepam in children without malaria but not in those with malaria. These findings highlight aetiology as playing a substantial role in effectiveness of treatment. In all the studies, respiratory depression was similar or less frequent with treatment with buccal midazolam, compared to treatment with rectal diazepam.
Buccal midazolam versus rectal diazepam
Buccal midazolam versus intravenous diazepam
A hospital-based study of 120 children (82 males; age range: 0-12 years) compared seizure termination within five minutes after treatment with 0.2 mg/kg of buccal midazolam versus 0.3 mg/kg of intravenous diazepam, irrespective of seizure duration or cause (Talukdar and Chakrabarty, 2009 
Intramuscular midazolam versus intravenous diazepam
Chamberlain and colleagues carried out a prospective, randomised study comparing intramuscular midazolam with intravenous diazepam for the treatment of seizures with a duration of at least 10 minutes in 24 children (Chamberlain et al., 1997) . The 13 children in the midazolam group received medication earlier (3.3±2.0 vs. 7.8±3.2 minutes, respectively; p=0.001) and their seizures terminated earlier (7.8±4.1 vs. 11.2±3.6, respectively; p=0.047) than those of the 11 children treated with diazepam.
Intramuscular midazolam versus intravenous lorazepam
The Rapid Anticonvulsant Medication Prior to Arrival Trial (RAMPART) study was a double-blind, randomised, non-inferiority trial of the effectiveness of intramuscular midazolam versus intravenous lorazepam in seizure management in the out-ofhospital setting for all age groups (Silbergleit et al., 2012) . In total, 145 paediatric patients among 893, overall, were enrolled. For those who were seizurefree upon arrival at hospital, there was no statistical difference among those treated with intramuscular midazolam (73%) versus treatment with intravenous lorazepam (63%), however, the rate of hospitalisation was lower in the intramuscular midazolam group (57.6 vs. 65.6%, respectively; relative risk: 0.88). This study highlights the potential for another non-intravenous out-of-hospital route of administration. However, the authors admitted that the cost of study autoinjectors, that were not commercially available and had been funded through the USA's Department of Defense, would have been prohibitively expensive for general usage. Respiratory depression (14%) and hypotension (1-2%) were comparable in both treatment groups.
Intramuscular diazepam versus placebo
Abou-Khalil et al. carried out a double-blind, randomised, placebo-controlled trial of a diazepam autoinjector administered by caregivers to patients with epilepsy who required treatment for acute 
Ease of delivery route and social acceptability
There is overwhelming evidence of a preference for nasal/oromucosal midazolam over rectal diazepam by families, carers, and affected children themselves (Wilson et al., 2004; Terry et al., 2007; Sofou et al., 2009 ). The preference is mainly due to better personal dignity for those being treated, the fact that buccal/intranasal routes are more socially appropriate, ease of administration for wheelchair users, and a perceived quicker response relative to rectal diazepam. A US 2003-2004 survey found that 19% (8/43) of parents reported that schools had refused to administer rectal diazepam, citing legal concerns behind their refusal (Terry et al., 2007) . A recent European review revealed that fear of liability was a critical issue for treatment with rectal diazepam by non-parental carers (Wait et al., 2013) . Early in the placebo-controlled trial of a diazepam autoinjector, the study was put on hold because three caregivers accidentally injected themselves while attempting to administer study medication to subjects. Thus, in addition to the common complications of pain at the site and haemorrhage in patients given intramuscular treatments, there is the potential for needle stick/injection injuries to care-givers.
Conclusion
Midazolam, clonazepam and lorazepam are all in principle viable options to diazepam for the treatment of prolonged seizures in children. For practical reasons, non-intravenous delivery options must be the mainstay of early emergency treatment of children with seizures out of hospital, and include treatment rectally, intranasally, buccally (via oromucosa), sublingually (via oromucosa), or intramuscularly. The evidence, thus far, is that buccal midazolam is superior to rectal diazepam, but beyond that, there are limited conclusions that can be made because of the limited randomised controlled trials comparing benzodiazepines delivered by different routes. There is marked diffidence towards treatment by the rectal route, and alternatives are at least as effective in seizure termination. There is rapid absorption by the nasal route but treatment by this route can theoretically be associated with marked nasal irritation, although this would be less of an issue in an acute convulsing child. There are also concerns surrounding this route of delivery because of a theoretical reduced absorption in children with upper respiratory tract infections, but this has to be counterbalanced by increased blood flow that may aid absorption. These theoretical concerns do not seem to have been borne out in practice, as a randomised controlled trial restricted to children with febrile seizures, many of whom had upper respiratory tracts, reported a high proportion of children successfully treated with nasal midazolam. However, why aim for a smaller moving target in the nares of children to deliver an intranasal preparation when there is a much bigger and easily accessible option close by for delivery of a buccal preparation? There is a theoretical risk of aspiration with buccal treatment but none of the studies on buccal midazolam above have reported this as a complication. Intramuscular injections cause local haemorrhage and are painful which would be a major deterrent for use in children, especially in those who require recurrent usage. It is evident from the studies included in this review that the optimum dose for the individual drugs, according to the varied delivery route options, remains unclear. The long-term effects of these medications and whether they have a neuroprotective effect beyond seizure termination is not known. Further studies in these areas, particularly randomised controlled trials, are needed.
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